ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Entero Therapeutics Inc

Entero Therapeutics Inc (ENTO)

0,4533
0,0383
(9,23%)
Fermé 24 Novembre 10:00PM
0,4108
-0,0425
(-9,38%)
Après les heures de négociation: 1:59AM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
0,4533
Prix Achat
0,4108
Prix Vente
0,4515
Volume échangé
50 133
0,39 Fourchette du Jour 0,46
0,185 Plage de 52 semaines 3,16
Clôture Veille
0,415
Ouverture
0,42
Dernière Transaction
5
@
0.4515
Dernière heure de transaction
Volume moyen (3 m)
423 060
Volume financier
US$ 21 093
VWAP
0,420738

ENTO Dernières nouvelles

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform...

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease

New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.0482-9.61116650050.50150.50150.38844460.43113162CS
4-0.2259-33.25971731450.67920.72080.381984220.59193923CS
120.046311.37592137590.4070.86550.284230600.56331302CS
26-2.4667-84.47602739732.922.990.1854767970.47554831CS
52-2.5067-84.68581081082.963.160.1854661320.47730788CS
156-2.5067-84.68581081082.963.160.1854661320.47730788CS
260-2.5067-84.68581081082.963.160.1854661320.47730788CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PDYNPalladyne AI Corporation
US$ 4,59
(129,50%)
83M
QMCOQuantum Corporation
US$ 9,11
(126,62%)
39,41M
NANano Labs Ltd
US$ 8,26
(89,02%)
2,03M
XCURExicure Inc
US$ 18,60
(71,27%)
4,36M
SKKSKK Holdings Limited
US$ 1,75
(59,09%)
95,06M
AMIXAutonomix Medical Inc
US$ 6,21
(-54,07%)
946,09k
CETXCemtrex Inc
US$ 0,1146
(-41,74%)
24,39M
MSWMing Shing Group Holdings Ltd
 5,90
(-35,52%)
417,08k
RMSGReal Messenger Corporation
US$ 3,09
(-26,25%)
313,51k
ENSCEnsysce Biosciences Inc
US$ 0,4414
(-25,49%)
4M
ELABElevai Labs Inc
US$ 0,0201
(-0,50%)
425,38M
NVDANVIDIA Corporation
US$ 141,95
(-3,22%)
236,51M
SMCISuper Micro Computer Inc
US$ 33,15
(11,62%)
159,61M
VRPXVirpax Pharmaceuticals Inc
US$ 0,5501
(-6,72%)
159,39M
SOUNSoundHound AI Inc
US$ 8,24
(18,05%)
107,91M
Aucune Discussion Trouvée
Ajouter une Discussion